ASPI & QLE: Revenue Projection Model & Valuation Analysis 2026–2030
3/23/26
SEQH CAPITAL RESEARCH – TEAR SHEET
ASPI & QLE REVENUE PROJECTION MODEL (2026–2030) – TEAR SHEET PREVIEW
ASP Isotopes Inc. (NASDAQ: ASPI) has transitioned from a pre-revenue isotope enrichment story into a vertically integrated critical materials platform with five independent, high-optionalitiy revenue vectors across helium/LNG, stable isotopes, radiopharmaceuticals, nuclear fuel, and nuclear waste remediation. The January 6, 2026 close of the Renergen transaction, underpinned by $750M of committed DFC and Standard Bank debt, plus the planned QLE spin-off, creates a dual-entity structure where public markets are still assigning minimal value to multiple near-term, contract-backed revenue streams. At a current market cap of ~$451M and share price of $4.83, our work suggests the risk/reward remains skewed heavily to the upside over the next 18–36 months.
ASPI REMAINCO: MULTI-SEGMENT REVENUE RAMP
ASPI RemainCo retains the non-HALEU core: Renergen helium/LNG, Si-28 and other stable isotopes, C-14, PET Labs, and non-core Skyline. Across 2026–2030, we model a step-change in revenue from single digits to a potential $239–344M range by 2030, with multiple segments capable of independently supporting the current market cap over time. Key building blocks include:
Renergen Phase 1 helium/LNG: Management-guided ~$20M annualized revenue at nameplate, with upside if helium prices remain elevated amid a supply shock that has removed roughly one-quarter to one-third of global supply.
Renergen Phase 2: 44‑month build post-Phase 1 completion, scaling to 895 MCF/day helium and 34,000 GJ/day LNG underpinned by $750M+ in committed project financing.
Si-28, C-14, Yb-176 and other isotopes: Three signed Si-28 contracts, a long-term take-or-pay C-14 agreement, and growing specialty isotope demand in quantum, industrial, and life sciences applications support a diversified, high-margin revenue mix.
PET Labs: The only currently profitable segment, with U.S. radiopharmacy roll-up strategy (5–8 sites targeted) and lutetium-177 therapeutics providing an additional defensible healthcare revenue stream.
QLE: EMERGING NUCLEAR FUEL PLATFORM
QLE holds the nuclear fuel rights to ASP’s aerodynamic separation process and its laser-based Quantum Enrichment technology, giving it a potential strategic footprint across lithium-7, lithium-6, HALEU/LEU+, helium-3, cesium-137 remediation (KUBE), and seawater-derived uranium via Supercritical. Post spin, ASPI will retain ~75% ownership. Our base case sees QLE scaling from effectively zero revenue in 2026 to a modeled $208–343M by 2030, with key vectors including:
Lithium-7: Addressing a critical bottleneck for existing PWR fleets and future molten salt reactors, where Western supply is effectively non-existent.
HALEU: Positioning as a potential second Western HALEU supplier alongside Centrus, targeting a DOE-projected multi-billion-dollar market as advanced reactors scale.
Diversified nuclear-fuel-adjacent revenue: Lithium-6 for fusion, helium-3 for advanced reactor concepts, and KUBE nuclear waste remediation as additive, high-optionalitiy legs.
VALUATION SNAPSHOT & MARGIN TRAJECTORY
Using a sum-of-the-parts framework anchored to nuclear fuel, uranium, and specialty isotope peers, we probability-weight segment-level valuations to derive an 18‑month fair value of ~$16 per share, implying >200% upside from current levels. The core of the thesis is not a distant blue-sky scenario, but the monetization of signed contracts, committed project finance, and visible capacity additions. As higher-margin isotope enrichment and helium production scale, we model consolidated gross margins expanding from the low 30% range to the high 60% range by 2030, with EBITDA margins inflecting from negative in 2026–2027 to potentially approaching ~50% by decade-end. Management’s $300M+ 2030 EBITDA target sits within our base-case range and, when valued at a discount to current nuclear peers, supports a long-term per-share value multiple turns above today’s price.
KEY NEAR-TERM CATALYSTS (NEXT 12 MONTHS)
Completion of the QLE spin-off and public listing, crystallizing standalone nuclear fuel value and clarifying the ASPI RemainCo story.
Renergen Phase 1C first commercial helium and LNG deliveries, validating project economics amid a tight helium market.
Execution on Si-28, C-14, and Yb-176 commercial contracts, supporting the transition from pre-revenue narrative to recurring, diversified cash flows.
PET Labs U.S. radiopharmacy expansion, including integration of initial acquisitions and continued build-out of theranostics capabilities.
WHAT PAID MEMBERS GET IN THE FULL PDF
Upgrade to access the full 7-page institutional report, including:
Detailed segment-by-segment revenue models for ASPI RemainCo and QLE from 2026–2030, with low/base/high cases and explicit assumptions for each product line.
Complete sum-of-the-parts valuation framework, including peer comps, scenario tables (bear/base/bull/accelerated), and probability-weighted price targets.
Full margin, EBITDA, and free cash flow trajectory analysis, with capex schedules, cash burn runway, and 2030 terminal value sensitivity across five scenarios.
Deep-dive on HALEU, lithium-7, and helium market structure, including DOE demand projections, supply chain bottlenecks, and QLE’s competitive positioning.
Comprehensive catalyst timeline and risk matrix, mapping the next 3–5 years of execution milestones, regulatory events, financing triggers, and key downside risks.
